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Summary  It  is  two  decades  since  the  ﬁrst  report  of  transcatheter  implantation  of  a  stented
aortic  valve  in  an  animal.  The  ﬁrst  implantation  of  a  transcatheter  aortic  valve  in  a  human  was
accomplished  just  one  decade  ago  dramatically  demonstrating  the  promise  and  feasibility  of
this  new  therapy.  Over  the  past  10  years,  there  have  been  rapid  developments  in  valves,  deli-
very  systems  and  technical  approaches.  Today,  transcatheter  valve  implantation  is  a  technical
possibility  for  the  great  majority  of  patients  with  aortic  stenosis.  The  next  10  years  may  well
see  this  become  the  dominant  therapy  for  aortic  stenosis.
©  2012  Elsevier  Masson  SAS.  
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Résumé  Deux  décennies  se  sont  écoulées  depuis  la  première  implantation  d’une  valve  sten-
tée  chez  l’animal.  La  première  implantation  d’une  valve  aortique  percutanée  chez  l’homme  a
été  réalisée,  il  y  a  juste  dix  ans,  avec  une  faisabilité  démontrée  et  des  perspectives  promet-
teuses.  Ces  dix  dernières  années  ont  connu  un  développement  technologique  rapide  que  ce
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aortique ;
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soit  sur  les  valves  elles-mêmes,  
l’implantation  de  valves  aortiqu
de  patients  porteurs  d’un  rétréc
années,  cette  technique  devienn
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Cet ales  dispositifs  de  délivrance  ou  les  voies  d’abord.  Aujourd’hui,
es  percutanées  est  techniquement  accessible  à  une  majorité
issement  aortique.  Il  est  possible  que  dans  les  dix  prochaines
e  le  traitement  prédominant  du  rétrécissement  aortique.
anscatheter heart valve.
e.
rticle est publié en Open Access sous licence CC BY-NC-ND.
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Figure 1. Early catheter-mounted valves. Parachute-like valves
offered  little resistance to the ﬂow of blood in one direction, but
obstructed  the ﬂow in the other. Animal studies suggested beneﬁt
in  the setting of aortic regurgitation.
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process is  not  without  complications  [15].  Coronary  obstruc-eprinted  with permission from Davies. 1965 [1] (A) and Phillips
t  al., 1976 [4] (B).
ackground
lmost  50  years  ago,  in  1965,  Hywel  Davies  placed  a
atheter-mounted valve  via  the  femoral  artery  into  the
escending aorta  of  a  dog  [1].  The  parachute-like  valve  was
riented so  as  to  passively  open  in  diastole  and  obstruct
etrograde ﬂow  in  the  patients  with  aortic  regurgitation.
ver the  subsequent  few  decades,  a  number  of  groups
xperimented with  various  catheter-mounted  passive  and
ctive temporary  valves  (Fig.  1).  These  valve  designs  were
ntended as  temporary  palliation  for  aortic  regurgitation  and
ere never  utilized  in  humans  [2—4].
The  ﬁrst  catheter  intervention  speciﬁcally  targeted  at
he stenotic  aortic  valve  was  aortic  balloon  valvuloplasty;
eveloped initially  as  a  therapy  for  congenital  aortic
tenosis, and  described  for  degenerative  aortic  stenosis
n adults  in  1986  by  Alain  Cribier  [5].  The  feasibility
f dilation  of  the  stenotic  calciﬁc  valve  provided  the
eed for  future  developments.  In  1992,  Henning  Ander-
en described  the  ﬁrst  transcatheter  aortic  stent  valve
6]. This  was  constructed  of  a  handmade  wire  frame
ithin which  was  sewn  a  porcine  aortic  valve  (Fig.  2).
he assembly  was  crimped  onto  a  balloon  catheter  and
mplanted transarterially  into  a  pig.  Subsequently,  a  num-
er of  groups,  including  our  own,  pursued  the  development
f a  practical  and  reliable  transcatheter  stent-mounted
alve suitable  for  implantation  in  humans  [7].  In  2000,
hilippe Bonhoeffer  described  a  bovine  jugular  venous  valve
ewn  within  a  large-diameter  stent,  which  was  implanted
ercutaneously in  children  with  pulmonary  conduits  [8];
roving the  feasibility  of  transcatheter  valve  implantation
n humans.However, it  was  in  2002,  10  years  ago,  that  Alain  Cribier
ccomplished the  ﬁrst  transcatheter  aortic  valve  implan-
ation (TAVI)  for  aortic  stenosis  [9];  opening  the  door  to
t
v
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 new  age  in  the  management  of  this  relatively  common
isease.
volution of transcatheter valves
alloon-expandable valves
he  original  Cribier-Edwards  valve  (Edwards  Lifesciences
nc., CA,  USA)  was  constructed  from  a laser-cut  stainless
teel tubular  frame  within  which  was  sewn  valve  leaﬂets
onstructed from  equine  pericardium,  with  the  inﬂow  cove-
ed with  a  fabric  sealing  cuff  (Fig.  3A).  This  valve  was  subse-
uently modiﬁed  as  the  Edwards  SAPIEN  transcatheter  heart
alve (THV)  (Fig.  3B),  incorporating  more  durable  bovine
ericardium, and  a  higher  sealing  cuff  to  reduce  paravalvu-
ar leaks  [10].
The SAPIEN  valve  was  subsequently  superseded  by  the
ow-proﬁle Edwards  SAPIEN-XT  valve  (Fig.  3C);  in  which
he stainless  steel  was  replaced  with  a  cobalt  chromium
lloy frame  [10,11].  This  alloy  allows  for  a  thinner,  stronger,
ore open  and  compressible  frame,  while  the  reengineered
eaﬂets ensure  valve  closure  even  when  closing  pressures
re low,  along  with  increased  durability.  Importantly,  this
alve was  designed  to  allow  the  use  of  smaller  diameter  18
rench delivery  systems.  The  SAPIEN-XT  valve  is  currently
anufactured with  diameters  of  20,  23,  26  and  29  mm.  Next-
eneration  SAPIEN  valve  systems  are  currently  undergoing
valuation, and  will  incorporate  additional  leaﬂet,  frame
nd sealing  enhancements  to  further  reduce  delivery  proﬁle
nd paravalvular  leaks.
oreValve
n  2005,  following  initial  implants  in  India,  early  German
xperience with  the  CoreValve  (Fig.  4)  was  reported  by
rube et  al.  [12].  The  valve  frame  was  constructed  of  niti-
ol; a  nickel-titanium  alloy  that  can  be  manufactured  so  as
o be  malleable  when  cool,  but  to  become  relatively  rigid  at
ody temperature.  The  valve  leaﬂets  and  annular  seal  were
onstructed of  porcine  pericardium.  The  valve  is  cooled  and
ompressed within  a  delivery  catheter,  which  is  then  placed
ithin the  diseased  valve.  As  a  covering  sheath  is  withdrawn,
he valve  is  released  and  expands,  returning  to  its  preset
hape. A  long  multi-staged  frame  is  anchored  within  the
ortic annulus  as  with  the  SAPIEN  valves,  but  also  extends
uperiorly to  anchor  in  the  supracoronary  aorta.  The  supra-
oronary portion  serves  to  self-centre  the  valve  and  provides
n additional  point  of  ﬁxation.  The  CoreValve  (Medtronic
nc., MN,  USA)  is  currently  available  with  diameters  of  26,
9 and  31  mm.
Only limited  non-randomized  comparisons  are  available
13,14]. Deployment  of  the  CoreValve  device  may  be  more
ntuitive, and  does  not  require  rapid  pacing,  while  deploy-
ent of  the  SAPIEN  device  may  be  more  targeted  and  clinical
eneﬁt is  better  documented.  The  CoreValve  device  can,
p to  a  point,  be  repositioned  or  retrieved,  although  thision is  rare,  but  more  of  a  concern  with  the  SAPIEN-type
alves. Atrioventricular  block  requiring  pacemaker  implan-
ation is  much  more  common  with  CoreValve.  Both  valves
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Figure 2. The Andersen valve. The valve was constructed of a handmade wire frame to which was sewn a porcine valve.
Reprinted with permission from Dr. Henning Andersen.
PIEN (B) and SAPIEN-XT (C) valves.Figure 3. Balloon-expandable valves. The Cribier-Edwards (A), SA
Reprinted with permission.
can  offer  dramatic  clinical  beneﬁt  and  both  systems  con-
tinue to  improve.
Newer valves
Several  newer  transcatheter  valves  (Fig.  5)  are  in  various
stages of  evaluation.  Some  are  in  clinical  use,  although  expe-
rience remains  very  limited  [16—18].  Generally,  these  newer
valves attempt  to  improve  on  the  widely  available  SAPIEN-XT
and CoreValve  devices  by  enhancing  deliverability,  position-
ing, sealing,  or  facilitating  repositioning  or  removal.
Some  valves  have  unique  expansion  mechanisms.  The
LotusTM valve  (Boston  Scientiﬁc  Inc.,  MN,  USA)  (Fig.  5A)
frame is  constructed  of  woven  nitinol  wires  which,  when
tensioned, cause  the  valve  to  decrease  in  height  while
increasing in  diameter  and  rigidity.  The  Direct  FlowTM valve
(Direct Flow  Medical  Inc.,  CA,  USA)  (Fig.  5B)  has  a  tubular
fabric frame  that  is  inﬂated  with  a  rapid-setting  polymer-
izing agent.  The  CENTERA  valve  (Edwards  Lifesciences  Inc.,
CA, USA)  (Fig.  5C)  is  released  from  its  constrained  state  by
Figure 4. Medtronic CoreValve.
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Figure 5. Newer valves: LotusTM valve (Boston Scientiﬁc Inc., MN, USA) (A); Direct FlowTM valve (Direct Flow Medical Inc., CA, USA) (B);
CENTERATM valve (Edwards Lifesciences Inc., CA, USA) (C); PorticoTM valve (St. Jude Medical Inc., MN, USA) (D); EngagerTM valve (Medtronic
Inc., MN, USA) (E); JenaClipTM valve (JenaValve Inc., Munich, Germany) (F); AcurateTM valve (Symetis, Ecublens, VD, Switzerland) (G); Braile
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salve (Braile Biomédica, Brazil) (H).
n  electric  motor.  However,  for  the  most  part,  these  valves
tilize self-expanding  heat-set  nitinol  frames  that  facilitate
hinner delivery  systems  and  repositioning.
Some  valves,  such  as  the  PorticoTM (St.  Jude  Medical
nc., MN,  USA)  (Fig.  5D)  and  AcurateTM (Symetis,  Ecublens,
D, Switzerland)  (Fig.  5G)  valves,  are  long  and  extend
nto the  supracoronary  aorta  to  assist  with  alignment  and
rovide additional  ﬁxation,  as  does  the  CoreValve  device.
ome, such  as  the  EngagerTM (Medtronic  Inc.,  MN,  USA)
Fig. 5E),  Acurate  (Symetis,  Ecublens,  VD,  Switzerland)
Fig. 5G),  and  JenaClipTM (JenaValve  Inc.,  Munich,  Ger-
any) (Fig.  5F)  valves,  incorporate  ﬂexible  arms  that
xtend above  the  native  leaﬂets  to  facilitate  positioning
nd rotational  orientation  in  relation  to  the  native  com-
issures and  coronaries.  These  newer  valves  are  generally
iming to  match  the  18  French  diameter  of  current  sys-
ems, although  16  French  and  even  14  French  systems  are
ery near.  The  Braile  valve  (Braile  Biomédica,  Brazil)  is
 balloon-expandable  valve,  perhaps  representing  a lower
ost alternative.
We can  expect  two  new  systems  from  Edwards  Life-
ciences Inc.  to  undergo  CE  mark  evaluation  in  the  near
uture. The  balloon-expandable  SAPIEN  3TM valve  will
ncorporate features  to  improve  paravalvular  sealing.  The
TMENTERA valve  (Fig.  5C)  will  offer  a  self-expandable  alter-
ative with  an  electric  motor  assisted  release  mechanism.
oth will  be  compatible  with  14  to  16  French  expandable
heath delivery  systems.
a
s
dvolution of approaches
ransvenous
he  ﬁrst  TAVI  procedures  were  performed  with  percuta-
eous femoral  venous  access,  with  transseptal  access  to  the
eft atrium,  mitral  valve,  left  ventricle,  and  then  antegrade
hrough the  aortic  valve  [9,19].  The  femoral  vein  was  easily
ble to  accommodate  the  large  sheath  required  for  the  bulky
ribier-Edwards valve  crimped  onto  a  standard  valvuloplasty
alloon. However,  the  procedure  was  complex,  difﬁcult  to
earn, and  complications  were  common.  Consequently  this
rocedure was  largely  abandoned  with  the  advent  of  the
ransarterial procedure  in  2005.
emoral arterial
he  retrograde  transarterial  femoral  procedure  was  devel-
ped concurrently  by  our  group  in  Canada  and  Grube  et  al.
n Germany  [20,21].  Transfemoral  arterial  access  resulted  in
 more  reproducible  and  generalizable  procedure,  and  was
argely responsible  for  the  rapid  uptake  of  TAVI  worldwide.
he main  initial  limitation  was  the  size  of  early  generation
ystems, ranging  from  22  to  25  French  in  diameter.The  large-diameter  CoreValve  delivery  system  was  rel-
tively well  suited  to  a  reduction  in  proﬁle,  and  18  French
ystems soon  became  available.  Signiﬁcant  reductions  in  the
iameter of  the  Edwards  systems  took  longer  due  to  the
Evolution  of  TAVI  157
Figure 7. The Edwards delivery systems. Retroﬂex delivery
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well to  this  approach  [25].  More  recently,  several  new  self-Figure 6. Medtronic CoreValve and the Accutrak delivery system.
additional  bulk  of  the  deployment  balloon.  However,  this
problem was  largely  solved  with  the  advent  of  the  current
low-proﬁle NovaﬂexTM system,  with  which  the  valved  stent
was introduced  into  the  sheath  ﬁrst  and  only  later  mounted
on the  balloon  after  both  had  been  passed  into  the  aorta.
Both  delivery  systems  have  undergone  a  number  of  ite-
rative changes  over  the  past  7  years.  In  addition  to  a
reduction in  proﬁle,  the  CoreValve  delivery  system  has
incorporated the  proprietary  Accutrak  stability  layerTM tech-
nology (Fig.  6),  which  markedly  reduced  the  forces  required
to retract  the  covering  sheath,  facilitating  relatively  more
accurate placement  of  the  valve.
The  Edwards  system  evolved  from  a  simple  valvuloplasty
balloon with  a  deﬂectable  pusher  RetroFlexTM catheter
(Fig. 7A),  to  the  RetroFlex  2  catheter  that  incorporated
a tapered  nosecone,  then  to  the  more  reﬁned  RetroFlex
3 catheter  (Fig.  7B).  The  nosecone  greatly  increased  the
ease of  passage  through  the  aortic  arch  and  stenotic  native
valve. The  Novaﬂex  (Fig.  7C)  and  the,  even  newer  and  yet
more reﬁned,  Novaﬂex  plus  (Fig.  7D)  catheters  incorporate
mechanisms for  aligning  the  SAPIEN-XT  valve  on  the  balloon,
allowing insertion  through  smaller  sheaths.  Numerous  other
minor modiﬁcations  allow  more  controlled  and  reliable  pas-
sage  through  the  aorta,  positioning  and  valve  deployment.
Both  the  Edwards  and  the  Medtronic  systems  initially
used large  22  to  25  French  sheath  introducers  designed  for
the introduction  of  aortic  endografts.  The  CoreValve  sys-
tem is  currently  reliant  on  off-the-shelf  18  French  sheaths
(Check-FloTM,  Cook  Medical  Inc.,  IN,  USA;  UltimumTM,  St.
Jude Medical  Inc.,  MN,  USA;  and  DrySheathTM,  Gore  Medi-
cal Inc.,  AZ,  USA).  Edwards  Lifesciences  developed  its  own
line of  sheath  introducers  and  dilators  speciﬁcally  designed
for this  purpose.  Recently,  a  14  French  expandable  sheath
has become  available  (SoloPathTM,  Onset  Medical  Corp.,  CA,
USA). Once  introduced  into  the  artery,  a  balloon  bonded
to the  obturator  is  used  to  dilate  the  stent-like  frame
of the  sheath  to  over  18  French,  minimizing  the  risk  of
e
a
Jatheter with the Cribier-Edwards valve (A); Retroﬂex 3 with the
APIEN  valve (B); Novaﬂex with the SAPIEN-XT valve (C); Novaﬂex
lus  (D).
rterial  injury  at  the  time  of  sheath  insertion.  Both
oreValve and  SAPIEN  versions  are  available.  The  EsheathTM
Edwards  Lifesciences  Inc.,  CA,  USA)  incorporates  a  fold  that
uns the  length  of  the  14,  16  or  18  French  sheath  and  dilates
ransiently as  the  SAPIEN-XT  valve  is  passed  through  it.
With  reduced  sheath  diameters  and  increased  expe-
ience, open  cutdown  is  progressively  giving  way  to
outine fully  percutaneous  access.  Most  operators  cur-
ently use  preclosure  with  either  the  ProstarTM or  ProglideTM
evices  (Abbott  Medical  Inc.,  IL,  USA).  With  lower-proﬁle
ystems, improved  screening  and  increased  expertise,  vas-
ular  complications  are  falling  markedly  in  experienced,
igh volume  centres  [22].  Femoral  transarterial  access
s currently  the  preferred  default  strategy  in  most  cen-
res.
pical
he  ﬁrst  transapical  valve  implantation  in  an  animal
odel was  performed  utilizing  an  early  self-expanding
alve in  Vancouver  in  2000  [7].  Walther  et  al.  implanted
he Cribier-Edwards  valve  with  the  left  ventricular  apex
xposed through  a  median  sternotomy  in  Leipzig  in  2006,
lthough paravalvular  regurgitation  required  conversion
o conventional  surgery  in  a  case  [23].  Successful  off-
ump implants  using  intercostal  access  were  successfully
ccomplished by  the  Vancouver  group  shortly  afterwards
24].
Initially, the  transfemoral  Retroﬂex  system  was  utilized.
owever, the  purpose-speciﬁc  Ascendra  delivery  catheter
as developed  shortly  afterwards.  This  has  now  been  super-
eded by  the  Ascendra  2  system  (Fig.  8),  which  is  lower
roﬁle, easier  to  de-air,  can  accommodate  the  SAPIEN-XT
alve, and  facilitates  use  by  a  single  operator.
Although  a  small  number  of  CoreValve  implants  have  been
erformed transapically,  this  system  does  not  lend  itselfxpandable systems  have  been  designed  to  take  speciﬁc
dvantage of  an  apical  approach;  implanting  the  Engager,
enaValve, Acurate  and  Portico  valves.
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Interv  2010;3:531—6.igure 8. Ascendra 2 transapical valve delivery catheter.
ransaxillary/subclavian
ccess  to  the  axillary  artery  and  passage  through  the  subcla-
ian artery  often  offers  an  appealing  alternative  in  patients
ith iliofemoral  disease  [26,27].  The  short  distance  and
on-tortuous course  to  the  aortic  valve  proved  particularly
dvantageous for  the  CoreValve  procedure.  Initial  concerns
ith respect  to  the  Novaﬂex  system,  due  to  the  need  for
alve alignment  in  a  relatively  straight  segment  of  the  aorta,
eem to  have  been  allayed.
Access  to  the  axillary  artery  has  generally  been  accom-
lished in  an  open  fashion,  due  to  the  thin  friable  wall
f this  artery,  although  the  feasibility  of  reliable  percuta-
eous access  and  closure  has  been  demonstrated.  However,
t is  necessary  to  assure  a  fallback  should  initial  attempts
t haemostasis  fail  in  this  non-compressible  artery,  making
his somewhat  more  complex  than  is  the  case  with  femoral
ccess.
ransaortic
irect  access  to  the  ascending  aorta  through  a  small
arasternal incision  is  much  more  within  the  comfort  zone
f the  cardiac  surgeon  uninitiated  to  left  ventricular  api-
al access  [28,29].  Although  this  avoids  the  risk  of  apical
r peripheral  vascular  injury,  there  are  still  concerns  with
espect to  aortic  injury  or  atheroembolism.  Although  the
rocedure has  generally  been  performed  with  the  standard
dwards or  Medtronic  transarterial  delivery  system,  we  can
nticipate  purpose-speciﬁc  systems  that  are  shorter  and
ave lower  proﬁles  to  facilitate  transaortic  retrograde  cross-
ng  of  the  aortic  valve.  It  seems  likely  that  this  approach  will
ecome increasingly  popular  in  patients  with  compromised
rterial access.
onclusions
n  the  decade  since  transcatheter  valve  implantation  was
rst accomplished  in  man,  there  have  been  tremendous
dvances. It  is  possible  to  speculate  that  the  next  10  years
ay well  see  TAVI  become  the  dominant  therapy  for  aortic
tenosis.
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